INDV (Indivior Pharmaceuticals) DeferredTaxAndRevenue: $0 Mil (As of Mar. 2026)


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $39.80
GF Value $22.95
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals DeferredTaxAndRevenue?

Indivior Pharmaceuticals INDV -1.12% 75 DeferredTaxAndRevenue is $0 Mil as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.95 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Indivior Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0 Mil.

Indivior Pharmaceuticals DeferredTaxAndRevenue Related Terms

Indivior Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals DeferredTaxAndRevenue Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0 Mil mean?
Indivior Pharmaceuticals (INDV) has a DeferredTaxAndRevenue of $0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Indivior Pharmaceuticals.
Is Indivior Pharmaceuticals' DeferredTaxAndRevenue too high?
Indivior Pharmaceuticals' current DeferredTaxAndRevenue is $0 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' DeferredTaxAndRevenue compare to KNSA and AMRX?
Indivior Pharmaceuticals' DeferredTaxAndRevenue of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Indivior Pharmaceuticals. Indivior Pharmaceuticals's current DeferredTaxAndRevenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.95, compared to a current price of $39.80 — trading 73.4% above its estimated fair value. The current DeferredTaxAndRevenue is $0 Mil. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current DeferredTaxAndRevenue is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $39.80 is trading 73.4% above its estimated GF Value™ of $22.95. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • DeferredTaxAndRevenue: $0 Mil
  • GF Value™: $22.95 vs. price of $39.80 (73.4% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.80
Price
$22.95
GF Value